Skip to main content
OpenTrials
Completed

NCT Number: NCT02416817

Strategy of Transfusion in Trauma Patients - STATA Trial

The purpose of this study is to compare two already validated methods for massive transfusion in trauma patients admitted to the emergency room of a large reference hospital.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hospital das Clínicas FMUSP

São Paulo, 05403-000, Brazil

About this study

In this randomized trial trauma patients in need of massive transfusion will be assigned to one of the following transfusion strategies:

  • - Fresh Frozen Plasma, Platelets Concentrate and Packed red blood cells in 1:1:1 ratio.
  • - These patients will receive Red blood cells based on Haemoglobin measurements and will receive either Beriplex® P/N (CSL Behring GmbH, Marburg, Germany) or Haemocomplettan® P (CSL Behring, Marburg, Germany), or Platelets based on thromboelastometry.

To be included patients must meet the following inclusion criteria:

  • - Trauma victims
  • - Adults between 18 - 80 years old
  • - Injury Severity Score (ISS) between 15 and 45
  • - Assessment of Blood Consumption (ABC) Score ≥ 3 points
  • - Shock Index ≥ 1,2
  • - Acute hemorrhage of more than 50% estimated blood volume in 3 hours or more than 1,5 ml/kg/min of blood during 20 minutes.

Exclusion criteria

  • - Early cardiac arrest
  • - Pregnancy
  • - Injury Severity Score (ISS) > 45
  • - Patient transferred from another hospital
  • - Drug abuse history
  • - Known coagulation impairment
  • - Known use of anticoagulants, or platelet antiaggregants.

The group of health-care providers recruiting the patients based on eligibility criteria, is different than the group that evaluates the clinical outcomes of the included patients, in such a way that no researcher is tasked with post-randomisation care of the subjects. This is done to prevent observational bias.

Two informed consent forms are signed for each patient. The first one is signed by an independent physician. Another consent form is signed by the patient's family or the own patient within 24 hours of hospital admission.

The randomisation is performed by sealed envelopes assigned to the eligible patients anytime they reach the protocol criteria. The envelopes were created using a computer generated randomisation table specifically designed to this study.

An interim analysis was performed in October 2015 and it showed that there was no increased mortality or morbidity within the intervention group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Trauma victims
  • Adults between 18 - 80 years old
  • Injury Severity Score (ISS) between 15 and 45
  • Assessment of Blood Consumption (ABC) Score ≥ 3 points
  • Shock Index ≥ 1,2

Exclusion criteria

  • Early cardiac arrest
  • Pregnancy
  • ISS > 45
  • Patient transferred from another hospital
  • Drug abuse history
  • Known coagulation impairment
  • Known use of anticoagulants, or platelet anti-aggregants. -

Treatment and study plan

Blood Products only

Other

Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.

Other names: Red blood cells, Platelets, Fresh frozen plasma

Point of Care guided

Other

Based on massive transfusion triggers and thromboelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the thromboelastometry. The dosis of each drug will be based on the analysis of the thromboelastometry curves (established algorithm).

Other names: Red blood cells, Beriplex® P/N (CSL Behring GmbH, Marburg, Germany), Haemocomplettan® P (CSL Behring, Marburg, Germany), Prothrombin Complex Concentrates (PCC), Human Fibrinogen

Primary outcomes

  1. SOFA Score - 5 days

    Time frame: 5 days

    Evaluation of the SOFA score along the first 5 days after the patient admission.

Sponsors and collaborators

Lead sponsor

University of Sao Paulo General Hospital

Other

Registry information

Official study title

Clinical Trial: Evaluation of 2 Different Protocols of Blood Derivates Transfusion in Acute Trauma Patients in a Brazilian Tertiary Hospital

Acronym: STATA

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Apr 15, 2015
Registry last updated
Nov 2, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.